Israel’s BioLineRX (see here previously) has partnered with Norway’s Hemispherian to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers.
Joint cancer treatment with Norwegian biotech
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.